Groundbreaking Study on Emerging Biomarker for Lung Cancer Treatment to be Presented at World Conference on Lung Cancer
Medical AI company Lunit has announced a groundbreaking collaborative study, to be presented at the 2023 World Conference on Lung Cancer (WCLC 2023), demonstrating the potential of AI-powered Tertiary Lymphoid Structures (TLS) analysis in predicting lung cancer treatment outcomes. Co-led by Lunit and esteemed medical institutions, the study demonstrates that TLS presence is strongly linked with improved overall survival in non-small cell lung cancer (NSCLC) patients.
United States Brandon Suh Northwestern University Feinberg School Of Medicine Chicago American Lung Association Mental Health Center Lunit Inc
Source: itnonline.com